9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 5

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: safety and tolerability,  maximum tolerated dose,  descriptive statistics of pharmacokinetic parameters including half life, clearnace, AUC, volume of distribution, fraction of patients with partial or complete response

Interventions: LMB-100, SEL-110

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: April 30, 2019

Completion Date: April 30, 2019

Last  Posted Date: June 14, 2019

Location: National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT03436732

Was this article helpful?
Dislike 0